GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BTAI · Sep 30, 2025

BioXcel Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001104659-25-109880General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

111352.04% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.00% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generation25thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-19170.41% · OPTIONAL · VALID

Revenue growth25thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

-54.21% · CORE · VALID

Inventory pressure58thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

468.37% · OPTIONAL · VALID

Gross margin50thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.gross_margin

88.78% · CORE · VALID

Operating margin25thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

-14518.37% · CORE · VALID

R&D intensity75thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

8918.37% · OPTIONAL · VALID

SBC intensity33thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

592.86% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20246/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/8 normalizedLevel 3Jun 30, 20256/8 normalizedLevel 3Sep 30, 20257/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20267/9 normalizedLevel 3Jun 30, 20267/9 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
90570.83%
Current
111352.04%
Delta
20781.21%
Cash Generation Decreased
Previous
-10479.17%
Current
-19170.41%
Delta
-8691.24%
Growth Increased
Previous
-89.13%
Current
-54.21%
Delta
34.92%
Inventory Pressure Increased
Previous
421.67%
Current
468.37%
Delta
46.70%
Margin Increased
Previous
10.83%
Current
88.78%
Delta
77.94%
Profitability Decreased
Previous
-13210.00%
Current
-14518.37%
Delta
-1308.37%
R And D Intensity Increased
Previous
8546.67%
Current
8918.37%
Delta
371.70%
Sbc Intensity Decreased
Previous
1296.67%
Current
592.86%
Delta
-703.81%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · BTAI Fundamental State →Transitioned To · BTAI Fundamental State →Transitioned To · BTAI BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · BTAI CASH_GENERATION_DECREASED →Transitioned To · BTAI GROWTH_INCREASED →Transitioned To · BTAI INVENTORY_PRESSURE_INCREASED →Transitioned To · BTAI MARGIN_INCREASED →Transitioned To · BTAI PROFITABILITY_DECREASED →Transitioned To · BTAI R_AND_D_INTENSITY_INCREASED →Transitioned To · BTAI SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.